Our Projects.
Horizon EU Heal, Proto, Nexgen.

Horizon EU
Heal
2022 - 2026
Broken Hearts
Deep Immune-Phenotyping of HLA-homozygous iPS-Cardiomyocytes

Horizon EU
Heal
2022 - 2026
Broken Hearts
Deep Immune-Phenotyping of HLA-homozygous iPS-Cardiomyocytes

Horizon EU
Heal
2022 - 2026
Broken Hearts
Deep Immune-Phenotyping of HLA-homozygous iPS-Cardiomyocytes

Horizon EU
Proto
2023 - 2027
Broken Bones
Mode of action & molecular mechanism of regenerative cell therapy in osteoarthritis

Horizon EU
Proto
2023 - 2027
Broken Bones
Mode of action & molecular mechanism of regenerative cell therapy in osteoarthritis

Horizon EU
Proto
2023 - 2027
Broken Bones
Mode of action & molecular mechanism of regenerative cell therapy in osteoarthritis

Horizon EU
Nexgen
2023 - 2027
EV Biomakers
Discovery of theranostic EV-based biomarkers of Parkinsons vaccination efficiency - Role of EV corona

Horizon EU
Nexgen
2023 - 2027
EV Biomakers
Discovery of theranostic EV-based biomarkers of Parkinsons vaccination efficiency - Role of EV corona

Horizon EU
Nexgen
2023 - 2027
EV Biomakers
Discovery of theranostic EV-based biomarkers of Parkinsons vaccination efficiency - Role of EV corona

CAR-NK-EV
CCS3
2024 - 2026
CAR-EV Biomarkers
Role of CAR-NK-derived EVs in leukemia cell lysis and immunomodulation

CAR-NK-EV
CCS3
2024 - 2026
CAR-EV Biomarkers
Role of CAR-NK-derived EVs in leukemia cell lysis and immunomodulation

CAR-NK-EV
CCS3
2024 - 2026
CAR-EV Biomarkers
Role of CAR-NK-derived EVs in leukemia cell lysis and immunomodulation

WISS25
GoodFibration
2024 - 2027
Scar-free Regeneration
Advancing scalable iPSC heart therapies for treating heart failure.

WISS25
GoodFibration
2024 - 2027
Scar-free Regeneration
Advancing scalable iPSC heart therapies for treating heart failure.

WISS25
GoodFibration
2024 - 2027
Scar-free Regeneration
Advancing scalable iPSC heart therapies for treating heart failure.

COST EU
Haplo.iPS
2022 - 2026
Universal Transplants
Developing HLA-homozygous hiPSC therapies, fostering collaboration, innovation, and inclusivity.

COST EU
Haplo.iPS
2022 - 2026
Universal Transplants
Developing HLA-homozygous hiPSC therapies, fostering collaboration, innovation, and inclusivity.

COST EU
Haplo.iPS
2022 - 2026
Universal Transplants
Developing HLA-homozygous hiPSC therapies, fostering collaboration, innovation, and inclusivity.